Recent technological updates and clinical applications of induced pluripotent stem cells.
10.3904/kjim.2014.29.5.547
- Author:
Sebastian DIECKE
1
;
Seung Min JUNG
;
Jaecheol LEE
;
Ji Hyeon JU
Author Information
1. Division of Cardiology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
- Publication Type:Review ; Research Support, Non-U.S. Gov't
- Keywords:
Induced pluripotent stem cells;
Reprogramming technique;
Gene editing;
Disease model;
Regenerative medicine
- MeSH:
Animals;
Cellular Reprogramming;
Drug Evaluation, Preclinical;
Gene Targeting;
Humans;
Induced Pluripotent Stem Cells/*cytology/*transplantation;
Mice;
Models, Biological;
Regenerative Medicine
- From:The Korean Journal of Internal Medicine
2014;29(5):547-557
- CountryRepublic of Korea
- Language:English
-
Abstract:
Induced pluripotent stem cells (iPSCs) were first described in 2006 and have since emerged as a promising cell source for clinical applications. The rapid progression in iPSC technology is still ongoing and directed toward increasing the efficacy of iPSC production and reducing the immunogenic and tumorigenic potential of these cells. Enormous efforts have been made to apply iPSC-based technology in the clinic, for drug screening approaches and cell replacement therapy. Moreover, disease modeling using patient-specific iPSCs continues to expand our knowledge regarding the pathophysiology and prospective treatment of rare disorders. Furthermore, autologous stem cell therapy with patient-specific iPSCs shows great propensity for the minimization of immune reactions and the provision of a limitless supply of cells for transplantation. In this review, we discuss the recent updates in iPSC technology and the use of iPSCs in disease modeling and regenerative medicine.
